Fewer needles, same results: monthly anemia drug effective for kidney patients

NCT ID NCT07025460

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This study tested whether a once-monthly injection of darbepoetin alfa can keep hemoglobin levels stable in people with advanced chronic kidney disease who are not on dialysis. 40 Korean adults who had stable hemoglobin on every-2-week dosing switched to monthly shots for 12 weeks. The monthly schedule successfully maintained hemoglobin at or above 10.0 g/dL, matching the effectiveness of the biweekly regimen. This simpler dosing could improve convenience and reduce healthcare visits for patients managing anemia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Institutional Review Board, Gangnam Severance Hospitial Yonsei University College of Medicine

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.